Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in Subjects With Primary Immunodeficiency

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.

Study Overview

• Status: Completed
• Conditions: Immunologic Deficiency Syndrome
• Intervention / Treatment: Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™

Detailed Description

This is an open-label, single-arm, historically controlled, prospective, multicenter phase III study to evaluate the safety, efficacy and pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in subjects with primary immunodeficiency diseases.

Subject will be infused every 21 to 28 days according to their previous IVIG treatment schedule. Subjects treated every 28 days will receive 13 study IVIG infusions. Subject treated every 21 days will receive 17 study IVIG infusions.

Duration of treatment:The total duration of treatment is 12 months.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M5G1X8
      • The Hospital for Sick Children
    • Toronto, Ontario, Canada, M4V1R2
      • Gordon Sussman Clinical Research Inc.
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • University of Alabama Hospital
  • Florida
    • North Palm Beach, Florida, United States, 33408
      • Allergy Associates of the Palm Beaches
  • Illinois
    • Chicago, Illinois, United States, 33408
      • Rush University Medical Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa Hospitals and Clinics
  • Ohio
    • Columbus, Ohio, United States, 43235
      • Optimed Research, LTD
  • Texas
    • Dallas, Texas, United States, 75231
      • AARA Research Center
    • Dallas, Texas, United States, 75230
      • Dallas Allergy Immunology
  • Virginia
    • Richmond, Virginia, United States, 23219
      • Children's Hospital of Richmond
  • Washington
    • Bellingham, Washington, United States, 98225
      • Bellingham Asthma, Allergy & Immunology Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 70 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects with a confirmed clinical diagnosis of a Primary Immunodeficiency Disease as defined by IUIS (International Union of Immunological Societies) and require treatment with IVIG. Documented agammaglobulinemia or hypogammaglobulinemia (preferably with documented antibody deficiency).
• Male or female, ages 2 to 70 years.
• The subject has received 300-900 mg/kg of a licensed IGIV therapy at 21 or 28 day intervals for at least 3 months prior to this study.
• At least 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months prior to study enrollment.
• Subject is willing to comply with all requirements of the protocol.
• Females of child-bearing potential with a negative urine pregnancy test and who agree to employ adequate birth control measures during the study.
• Subject, parent or guardian has signed the informed consent form and a child assent form if appropriate. Pediatric subjects are defined as 2-17 years of age at study entry and will require assent forms as appropriate per study documentation and regulations of the local jurisdiction.
• Authorization to access personal health information.
• Subjects currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving IVIG-SN™ and all inclusion and exclusion criteria are satisfied. Other IVIGs will be prohibited between the first infusion of IVIG-SN™ and Follow Up Visit 1.
• Subjects currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrollment in this study.

Exclusion Criteria:

• Subject has secondary immunodeficiency.
• Subject was newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
• Subject has a history of repeated reactions or hypersensitivity to IVIG or other injectable forms of IgG.
• Subject has a history of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism or transient ischemic attacks, or myocardial infarction, as defined by at least 1 event in subject's lifetime.
• Subject has IgA deficiency and is known to have antibodies to IgA.
• Subject has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrollment.
• Subject has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
• Subject has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
• Subject has a known history or is positive at enrollment for human immunodeficiency virus (HIV) type 1/2 by NAT or hepatitis B virus (HBsAg and NAT) or hepatitis C virus (by NAT), or hepatitis A virus (by NAT).
• Subject has levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
• Subject is using an implanted venous access device
• Subject has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3).
• Subject has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, or hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
• Subject has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrollment.
• Subject has history of epilepsy or multiple episodes of migraine not completely controlled by medication.

• Subject is receiving the following medication:

  • Steroids (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent).
  • Other immunosuppressive drugs or chemotherapy.
• Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
• Subject has participated in another clinical study within 3 weeks prior to study enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IVIG-SN™; Immune Globulin Intravenous (Human) 5% Liquid	Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™; IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.; Other Names: IGIV; Immune Globulin Intravenous (Human) 5% Liquid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of acute serious bacterial infections	one year
Overall incidence of adverse events that occur during or within 1 hour, 24 hours and 72 hours following an infusion of test product	Within 72 hours after treatment with IVIG-SN
The Pharmacokinetic (PK) Area under the curve (AUC0-t, AUC0-inf) of Immunoglobulin G (IgG).	After 5th infusion
The Pharmacokinetic (PK) Maximum concentration (Cmax) of Immunoglobulin G (IgG).	After 5th infusion

Secondary Outcome Measures

Outcome Measure	Time Frame
The number of days missed work/school/kindergarten/day care or unable to perform normal daily activities due to infection.	one year
Days of unscheduled physician visits and hospitalizations due to infection	One year
Number of days on therapeutic antibiotics	One year
The incidence of infections other than acute serious bacterial infections	One year
Annual rate of fever episodes per patient	One year
All adverse events regardless of causality assessment by investigator	One year
The proportion and number of IGIV infusions for which the infusion rate was decreased due to adverse events	One year
The proportion of adverse events considered by the investigator to be product related	One year
To monitor viral safety (freedom from transmission of blood borne virus diseases)	One year
Descriptive analyses of PK parameters for specific antibodies (anti-Hemophilus influenza type b, anti-Streptococcus pneumonia serotypes, anti-Tetanus toxoid, anti-cytomegalovirus (CMV), anti-measles) will be performed.	One year

Collaborators and Investigators

• Sponsor: Green Cross Corporation
• Collaborators: Atlantic Research Group

Study record dates

Study Major Dates

• Study Start: September 1, 2011
• Primary Completion (Actual): July 1, 2013
• Study Completion (Actual): July 1, 2013

Study Registration Dates

• First Submitted: July 26, 2011
• First Submitted That Met QC Criteria: July 29, 2011
• First Posted (Estimate): August 1, 2011

Study Record Updates

• Last Update Posted (Estimate): January 10, 2014
• Last Update Submitted That Met QC Criteria: January 9, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Keywords: Immunoglobulin G; Primary Immune Deficiency; IGIV
• Additional Relevant MeSH Terms: Immune System Diseases; Genetic Diseases, Inborn; Immunologic Deficiency Syndromes; Primary Immunodeficiency Diseases; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Immunoglobulins; Immunoglobulins, Intravenous; gamma-Globulins; Rho(D) Immune Globulin; Immunoglobulin G
• Other Study ID Numbers: IVIG_SN_P3 (Other Grant/Funding Number: Green Cross Corporation)